SAN DIEGO--(BUSINESS WIRE)--858 Therapeutics, a clinical-stage biotechnology company, today announced preliminary safety and efficacy data from its ongoing, first-in-human Phase 1/2 trial of PARG inhibitor ETX-19477. These data will be presented in a poster session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on Saturday, May 30. The ASCO abstract released today includes clinical data from 45 patients enrolled in the Phase 1a/b dose escalation and expansion portions o